Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder

Human Psychopharmacology

Volumn 26, Issue 7, 2011, Pages 451-459

  Jerrell, Jeanette M ^a   McIntyre, Roger S ^b   Tripathi, Avnish ^c  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

antidepressants; antipsychotics; comorbid medical conditions; pediatric bipolar disorder; psychostimulants

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; PSYCHOSTIMULANT AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ARTICLE; ASTHMA; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; CHILD DEVELOPMENT; CHILD PSYCHIATRY; CHILDHOOD; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; OBESITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 80755175783     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1227     Document Type: Article

References (74)

1. Ananth J, Parameswaran S, Gunatilake S,. 2004. Side effects of atypical antipsychotic drugs. Curr Pharm Des 10: 2219-2219.
2. Burke MJ, Lincoln J,. 2006. Mood disorders. In Conn's Current Therapy 2006, Bakel, RE, Bope, ET, (eds). WB Saunders Co: Philadelphia PA, 1361-1370.
3. Cassidy F, Ahearn E, Carroll BJ,. 1999. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 156: 1417-1420. (Pubitemid 29416540)
4. Chen JL, Spinowitz N, Karwa M,. 2003. Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possible associate with mirtazapine: a case report. Pharmacotherapy 23: 940-944. (Pubitemid 36875677)
5. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT,. 2004. Second generation antipsychotic medications in children and adolescents. J Child and Adolesc Psychopharm 14: 372-394. (Pubitemid 39473123)
6. Cohen D, Gerardin P, Mazet P, Purper-Ouakil D, Flament MF,. 2004. Pharmacological treatment of adolescent major depression. J Child Adolesc Psychopharm 14: 19-31. (Pubitemid 38525950)
7. Correll CU,. 2007. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Acad Child Adolesc Psychiatry 46 (6): 687-700. (Pubitemid 46816822)
8. Correll CU, Carlson HE,. 2006. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45: 771-791. (Pubitemid 43932904)
9. Correll CU, Penzner JB, Parikh UH, et al,. 2006. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatric Clin N Am 15: 177-206. (Pubitemid 41735243)
10. Coulter DM, Pillans PI,. 1995. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 152: 122-125.
11. Damsa C, Bumb A, Bianchi-Demicheli F, et al,. 2004. "Dopamine dependent" side effects of SSRIs: a clinical review. J Clin Psychiatry 65: 1064-1068.
12. Devane CL, Sallee FR,. 1996. SSRIs in child and adolescent psychiatry: a review of published experience. J Clin Psychiatry 57: 55-66.
13. Ellsworth AJ, Witt DM, Dugdale DC, et al,. 2006. Mosby's Medical Drug Reference. Mosby: St. Louis, MO.
14. Fagiolini A, Frank E, Scott JA, et al,. 2005. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disorders 7: 424-430. (Pubitemid 41419409)
15. Fagiolini A, Frank E, Houck PR, et al,. 2002. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 63: 528-533. (Pubitemid 34680363)
16. Fedorowicz VJ, Fombonne E,. 2005. Metabolic side effects of atypical antipsychotics in children: a literature review. J Psychopharmacol 9: 533-550. (Pubitemid 41392308)
17. Fenn HH, Bauer MS, Altshuler L, et al,. 2005. Medical comorbidity and health-related quality of life in bipolar disorder across the adult age span. J Affect Disord 86: 47-60. (Pubitemid 40487959)
18. Findling RL, Steiner H, Weller EB,. 2005. Use of antipsychotics in children and adolescents. J Clin Psychiatry 66 (suppl 7): 29-40. (Pubitemid 41345492)
19. Fleischhacker WW, Cetkovich-Bakmas M, DeHert M, et al,. 2008. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 69: 514-519. (Pubitemid 351792324)
20. Francis PD,. 2002. Effects of psychotropic medications on pediatric electrocardiogram and recommendations for monitoring. Curr Opin Pediatr 14: 224-230. (Pubitemid 34412169)
21. Gold Standard, Inc. 2008. Citalopram, Escitalopram, Fluoxetine, Fluoxetine + Olanzapine, Fluvoxamine, Paroxetine, and Sertraline: Adverse Reactions. MD Consult [database]. University of South Carolina School of Medicine Library, Columbia, SC. Accessed January 30, 2008.
22. Hirschfeld RMA,. 2005. The role of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 66 (suppl 3): 3-4. (Pubitemid 40461405)
23. Holmberg SK, Kane C,. 1999. Health and self-care practices of persons with schizophrenia. Psychiatr Serv 50: 827-829. (Pubitemid 29258962)
24. Hu XH, Bull SA, Hunkeler EM, et al,. 2004. Incidence and duration of side effects and those rated as bothersome with SSRI treatment for depression: patient report versus physician estimate. J Clin Psychiatry 65: 959-965.
25. Jensen PS, Buitelaar J, Pandina GJ, et al,. 2007. Management of psychiatric disorders in children and adolescents with atypical antipsychotics. Eur Child Adolesc Psychiatry 16: 104-120.
26. Jerrell JM, McIntyre RS, Tripathi A,. 2011. A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. J Clin Psychiatry 71 (11): 1518-1525.
27. Johannessen L, Strudsholm U, Foldager L, Munk-Jorgensen P,. 2006. Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord 95: 13-17. (Pubitemid 46110785)
28. Kessler RC, Crum RM, Warner LA, et al,. 1997. Lifetime co-occurrence of DSM-II-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 54: 313-321. (Pubitemid 27171916)
29. Kilbourne AM, Cornelius JR, Han X, et al,. 2004. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disorders 6: 368-373. (Pubitemid 39345287)
30. Krishnan KRR,. 2005. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med 67: 1-8.
31. Leverich GS, Post RM, Keck PE, et al,. 2007. The poor prognosis of childhood-onset bipolar disorder. J Pediatr 150: 485-490. (Pubitemid 46628810)
32. Lurie N, Popkin M, Dysken M, et al,. 1992. Accuracy of diagnosis of schizophrenia with Medicaid claims. Hospital Community Psychiatry 43: 69-71.
33. Mark TL, Buck JA, Dilonardo JD, et al,. 2003. Medicaid expenditures on behavioral health care. Psychiatr Serv 54: 188-194. (Pubitemid 36752849)
34. Masand PS, Gupta S,. 2002. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 14 (3): 175-182. (Pubitemid 36172566)
35. Magulac M, Landsverk J, Golshan S, Jeste DV,. 1999. Abnormal movements in neuroleptic-naîve children and adolescents. Can J Psychiatry 44: 368-373. (Pubitemid 29369359)
36. Masi G, Mucci M, Pari C,. 2006. Children with schizophrenia: clinical picture and pharmacological treatment. CSN Drugs 20: 841-866. (Pubitemid 44484247)
37. McClellan J, Sikich L, Findling RL, et.al. 2007. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and Methods. J Amer Acad Child and Adolescent Psychiatr 46: 969-978. (Pubitemid 47220681)
38. McConville BJ, Sorter MT,. 2004. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 65 (suppl 6): 20-29.
39. McElroy S, Allison D, Bray G,. Obesity and Mental Disorders. 2006. Taylor & Francis Press: New York.
40. McIntyre RS,. 2008. Considering wellness in managing patients with bipolar disorder. CNS Spectr 13 (6 Suppl 10): 7-8.
41. McIntyre RS, Jerrell JM,. 2008. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adol Med 162 (10): 929-935.
42. McIntyre RS, Jerrell JM,. 2009. Polypharmacy in children and adolescents with major depressive disorder. J Clin Psychiatry 70 (2): 240-246.
43. McIntyre RS, Konarski JZ,. 2005. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 66 (Suppl 3): 28-36. (Pubitemid 40461409)
44. McIntyre RS, Konarski JZ, Misener VL, et al,. 2005. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 17: 83-93. (Pubitemid 40967131)
45. McIntyre RS, Konarski JZ, Soczynska JK, et al,. 2006. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv 57 (8): 1140-1144. (Pubitemid 44204907)
46. McIntyre RS, Konarski JZ, Wilkins K, et al,. 2006. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry 51: 274-280. (Pubitemid 43764709)
47. McIntyre RS, Konarski JZ, Yatham LN,. 2004. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol 19: 369-386. (Pubitemid 39172802)
48. McIntyre RS, Nguyen HT, Soczynska JK, et al,. 2008. Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities. Dialogues Clin Neurosci 10 (2): 203-213. (Pubitemid 352028222)
49. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH,. 2006. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Safety 5: 157-168. (Pubitemid 43056447)
50. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH,. 2006. The effect of antidepressants on lipid homeostasis: a cardiac safety concern. Expert Opin Drug Safety 5: 523-537. (Pubitemid 44468450)
51. Michelson D, Faries D, Wernicke J, et al,. (Atomoxetine ADHD Study Group). 2001. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108: E83.
52. Moreno C, Laje G, Blanco C, et al,. 2007. National trends in the outpatient diagnosis and treatment of bipolar youth. Arch Gen Psychiatry 64: 1032-1039. (Pubitemid 47360848)
53. MTA Cooperative Group. 2004. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113: 762-769.
54. Nasrallah H,. 2002. Pharmacoeconomic implications of adverse effects during antipsychotic drug therapy. Am J Health Syst Pharm 59: S16-S21. (Pubitemid 35304083)
55. Pacher P, Kecskemeti V,. 2004. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharmaceutical Design 10: 2463-2475. (Pubitemid 38997427)
56. Pine DS, Goldstein RB, Wolk S, et al,. 2001. The association between childhood depression and adulthood body mass index. Pediatrics 107: 1049-1056. (Pubitemid 32440610)
57. Perlis RH, Miyahara S, Marangell LB, et al,. 2004. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 55: 875-881. (Pubitemid 38526299)
58. Post RM, Kowatch RA,. 2006. The health care crisis of childhood-onset bipolar illness: some recommendations for its amelioration. J Clin Psychiatry 67: 115-125. (Pubitemid 43213292)
59. Regenold WT, Thapar RK, Marano C, et al,. 2002. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 70: 19-26. (Pubitemid 34756609)
60. Ruzickova M, Slaney C, Garnham J, et al,. 2003. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry 48: 458-461. (Pubitemid 37295203)
61. Sikich L, Hamer RM, Bashford RA, et al,. 2004. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29: 133-145. (Pubitemid 38068023)
62. Simon GE, VonKorff M, Saunders K, et al,. 2006. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 63: 824-830.
63. Skowron DM, Stimmel GL,. 1992. Antidepressants and the risk of seizures. Pharmacotherapy 12: 18-22.
64. Stahl SM, Mignon L, Meyer JM,. 2009. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scan 119: 171-179.
65. Stigler KA, Potenza MN, McDougle CJ,. 2001. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 3: 927-942. (Pubitemid 34074818)
66. Stinson FS, Grant BF, Dawson DA, et al,. 2005. Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 80: 105-116. (Pubitemid 41266966)
67. Strakowski SM, DelBello MP, Fleck DE, Arndt S,. 2000. The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry 48 (6): 477-485.
68. Strakowski SM, DelBello MP, Fleck DE, et al,. 2007. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry 64: 57-64. (Pubitemid 46041739)
69. Thompson WK, Kupfer DJ, Fagiolini A, et al,. 2006. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trail. J Clin Psychiatry 67: 783-788. (Pubitemid 43946185)
70. To SE, Zepf RA, Woods AG,. 2005. The symptoms, neurobiology, and current pharmacological treatment of depression. J Neurosci Nurs 37 (2): 102-107.
71. Toren P, Ratner S, Laor N, Weizman A,. 2004. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Safety 27: 1135-1156. (Pubitemid 39647854)
72. Unutzer J, Simon G, Pabiniak C, Bond K, Katon W,. 2000. The use of administrative data to assess quality of care for bipolar disorders in a large staff model HMO. Gen Hosp Psychiatry 22 (1): 1-10. (Pubitemid 30129086)
73. Velamoor VR,. 1998. Neuroleptic malignant syndrome: recognition, prevention, and management. Drug Safety Concept 19 (1): 73-82.
74. Wang PW, Sachs GS, Zarate CA, et al,. 2006. Overweight and obesity in bipolar disorders. J Psychiatry Res 40: 762-764. (Pubitemid 44486246)